American Journal of Kidney Diseases
Volume 42, Supplement 1 , Pages 13-17, July 2003

Volume control and blood pressure management in patients undergoing quotidian hemodialysis

  • Gihad Nesrallah, MD

      Affiliations

    • Optimal Dialysis Research Unit, London Health Sciences Centre, London, Ontario, Canada
  • ,
  • Rita Suri, MD

      Affiliations

    • Optimal Dialysis Research Unit, London Health Sciences Centre, London, Ontario, Canada
  • ,
  • Louise Moist, MD

      Affiliations

    • Optimal Dialysis Research Unit, London Health Sciences Centre, London, Ontario, Canada
  • ,
  • Claude Kortas, MD

      Affiliations

    • Optimal Dialysis Research Unit, London Health Sciences Centre, London, Ontario, Canada
  • ,
  • Robert M Lindsay, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Robert M. Lindsay, MD, Optimal Dialysis Research Unit, London Health Sciences Centre, Westminster Campus, 800 Commissioners Rd East, London, ON, Canada N6A 4G5
    • Optimal Dialysis Research Unit, London Health Sciences Centre, London, Ontario, Canada

Abstract 

Background:

Hypertension and interdialytic weight gain are associated with left ventricular hypertrophy (LVH), an important predictor of cardiovascular mortality in hemodialysis (HD) patients.

Methods:

In the London Daily/Nocturnal Hemodialysis Study, a group of patients receiving quotidian HD, either short daily (n = 11) or long nocturnal (n = 12), were followed for up to 18 months. Patients were assessed for effects of quotidian HD therapy on blood pressure, interdialytic weight gain, extracellular fluid volume (ECFV), intensity of antihypertensive therapy, and homocysteine levels.

Results:

Significant reductions in predialysis mean arterial blood pressure were observed in the daily HD group at 6 months (P < 0.04) and in the nocturnal HD group at 9 months (P < 0.03); these improvements persisted throughout the study period. The daily HD group had a 60% reduction in mean number of antihypertensive tablets per day at 1 month and an 8.8-fold reduction by 18 months. Nocturnal HD patients experienced a 3.3-fold reduction, and control patients, a 1.4-fold increase in mean number of tablets per day by 18 months. By 3 months, the daily HD group showed a significant decrease in interdialytic weight gain (P < 0.0005) and lower ECFV than controls (P < 0.05). The nocturnal HD group had a transient, but significant, increase in interdialytic weight gain at 6 and 15 months (P < 0.05) and no difference in ECFV compared with controls, suggesting a different mechanism of blood pressure control. Homocysteine levels were significantly lower for both quotidian HD groups compared with conventional HD patients.

Conclusion:

Quotidian HD is a promising therapy with potent antihypertensive effects, resulting in improved blood pressure control. This, together with improved homocysteine levels, may be beneficial in the long term with regard to cardiovascular mortality.

Keywords:  Quotidian hemodialysis (HD), daily hemodialysis (HD), nocturnal hemodialysis (HD), blood pressure, interdialytic weight gain, extracellular fluid volume (ECFV), homocysteine

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 The London Daily/Nocturnal Dialysis Study was totally financed by a grant from the Ministry of Health and Long-Term Care of the Province of Ontario, Canada. The publication of this supplement was supported by grants from the Ministry of Health and Fresenius Medical Care of North America.

PII: S0272-6386(03)00532-8

doi:10.1016/S0272-6386(03)00532-8

American Journal of Kidney Diseases
Volume 42, Supplement 1 , Pages 13-17, July 2003